Vudalimab
As of the edition of 20 October 2026, Vudalimab is an antibody: stopped in 2026; acts on CTLA4 and PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Antibody
- Registered trials
- 8, 2 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Digestive system; Pregnancy and women's health; Blood and lymph; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 6 | 2 | 1 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Xencor | Lead sponsor of trials | 2018 to now |